İlknur KALELI, Ahmet ÇALIŞKAN, Büşra DÖNMEZ, Sedef Zeliha ÖNER, Tuğba SARI, Saniye KÜÇÜKAKIN YAKA, Mücahit SEÇME

Determination of COVID-19 PCR positivity and mutation status in coronaVac vaccinated individuals in Turkey

Background/aim: CoronaVac is an inactivated virus-based COVID-19 vaccine used in Turkey and approved for emergency use by the World Health Organization (WHO). In this study, it was aimed to retrospectively evaluate the mutation status and clinical status in individuals who received two doses of CoronaVac vaccine and were infected with COVID-19 at least two weeks after the second dose. Materials and methods: 164 people were included in the study and COVID-19 diagnosis and mutation analyses were determined by RT-PCR using the Bioseepdy SARS CoV-2 Double Gene RT-qPCR Kit and the Biospeedy SARS-CoV-2 Variant Plus kit in accordance with the protocol determined by the manufacturer. Results: 116 (70.7%) UK (Alpha, B.1.1.7) mutation and 3 (1.8%) South Africa (Beta, B.1.351), Brazil (Gamma, P.1) mutations were determined in 164 double doses CoronaVac vaccinated patients; 45 (27.5%) patients were mutation negative. Nine patients (5.5%) developed pneumonia. Eight patients (4.9%) had CT findings compatible with corona virus infection. Seven (4.3%) of the patients received treatment in the intensive care unit, and 5 (3%) of the patients were intubated. Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine significantly reduces the need for hospitalization, CT findings and intensive care.

PDF

___

1. Weston S, Frieman MB. COVID-19: Knowns, Unknowns, and Questions. mSphere 2020;5(2):e00203-20. doi:10.1128/ mSphere.00203-20
2. Khan S, Siddique R, Shereen MA, Ali A, Liu J et al. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of clinical microbiology 2020;58(5): e00187-20. doi:10.1128/ JCM.00187-20
3. Wu A, Peng Y, Huang B, Ding X, Wang X et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 2020;11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001
4. Maxmen A. One million coronavirus sequences: popular genome site hits mega milestone. Nature 2021;593(7857): 21. doi:10.1038/d41586-021-01069-w
5. Martin MA, VanInsberghe D, Koelle K. Insights from SARSCoV-2 sequences. Science 2021;371(6528): 466-467. doi:10.1126/ science.abf3995
6. Rahman M, Shirin T, Rahman S, Rahman MM, Hossain ME et al. The emergence of SARS-CoV-2 variants in Dhaka city, Bangladesh. Transboundary and Emerging Diseases 2021; 68(6): 3000-3001. doi: 10.1111/tbed.14203
7. Shen L, Bard JD, Triche TJ, Judkins AR, Biegel JA, Gai X. Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerging Microbes & Infections 2021;10(1):1293- 1299. doi: 10.1080/22221751.2021.1943540
8. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD et al. Comprehensive mapping of mutations in the SARSCoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021; 29(3): 463– 476.e6. doi:10.1016/j. chom.2021.02.003
9. Jia Z, Gong W. Will Mutations in the Spike Protein of SARSCoV-2 Lead to the Failure of COVID-19 Vaccines? Journal of Korean Medical Science 2021; 10;36(18): e124. doi: 10.3346/ jkms.2021.36.e124
10. Di Caro A, Cunha F, Petrosillo N, Beeching NJ, Ergonul O et al. Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations. Clinical Microbiology and Infection 2021;27(6):823-826. doi: 10.1016/j.cmi.2021.03.011
11. Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatology International 2021;41(8):1429-1440. doi: 10.1007/s00296-021-04910-7
12. Gao Q, Bao L, Mao H, Wang L, Xu K et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;3;369(6499):77-81. doi: 10.1126/science.abc1932
13. Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. Journal of Infection 2021;82(3):399-406. doi: 10.1016/j. jinf.2021.01.020
14. Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. Journal of Infection 2021;83(2):e20-e21. doi: 10.1016/j.jinf.2021.06.005
15. Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature 2021;589(7842):337-338. doi: 10.1038/d41586-021-00065-4
16. Shen L, Bard JD, Triche TJ, Judkins AR, Biegel JA, Gai X. Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications. Emerging Microbes & Infections 2021;10(1):885-893. doi: 10.1080/22221751.2021.1922097
17. Zhang Y, Zeng G, Pan H, Li C, Hu Y et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases 2021;21(2):181-192. doi: 10.1016/S1473- 3099(20)30843-4
18. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A et al. Efficacy and safety of an inactivated whole-virion SARSCoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;17;398(10296):213-222. doi: 10.1016/S0140- 6736(21)01429-X
19. Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S et al. A phase III, observer-blind, randomized, placebocontrolled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine 2021;22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052
20. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020; 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577
21. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC et al. Durability of Responses after SARS-CoV-2 mRNA1273 Vaccination. New England Journal Of Medicine 2021;7;384(1):80-82. doi: 10.1056/NEJMc2032195
22. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/ BioNTech and Moderna Vaccines. European Review for Medical and Pharmacological Sciences 2021;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877
23. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nature Communications 2021;28;12(1):3991. doi: 10.1038/s41467- 021-24285-4
24. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine. 2021;2;385(10):875-884. doi: 10.1056/NEJMoa2107715